================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB/A
----------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
For the quarterly period ended December 31, 1998
Amending Item 2. (Management's Discussion and Analysis
of Financial Condition and Results of Operations)
Date of Report (date of earliest event reported)
FEBRUARY 15, 1999
----------
SCANTEK MEDICAL, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-27592 84-1090126
- -------------------------------- ----------------- ------------------
(State or other jurisdiction of (Commission File (I.R.S. Employer
Incorporation or organization) Number) Identification No.)
321 PALMER ROAD, DENVILLE, NEW JERSEY 07834
(973) 366-5250
(Address and telephone number, including area code,
of registrant's principal executive office and zip code)
================================================================================
<PAGE>
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
During November 1998, HumaScan issued a statement concerning the ability of
the company to continue as a going concern. As a result of these concerns,
HumaScan failed to pay license fees, royalties and other sums due to the Company
for the period through January 31, 1999 totaling Seven Hundred Fifty Thousand
($750,000) Dollars. On December 21, 1998, Scantek sent HumaScan a notice of
default pursuant to the License Agreement. On March 12, 1999, the Company
entered into a Settlement Agreement with HumaScan. The transaction closed on
March 15, 1999. For more details with respect to this transaction see the
Company's Form 8-K filed with the Securities and Exchange Commission on April
2, 1999.
Certain statements in this amendment with respect to future expectations
and plans may be regarded as "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21F of the Securities
Exchange Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements including, but not limited to,
statements with respect to future earnings, and all other forward-looking
statements involve risks and uncertainties and are subject to change at any
time. The Company's actual results could differ materially from such statements.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrants have duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized
Date: April 1, 1999 SCANTEK MEDICAL, INC.
By: /s/ ZSIGMOND L. SAGI
--------------------------
Zsigmond L. Sagi
Title: President
-3-
